Skip to main content
Top
Published in: Rheumatology International 4/2017

01-04-2017 | Biomarkers

Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy

Authors: Yizhi Xiao, Hui Luo, Bin Zhou, Xiaodan Dai, Jing Huang, Liping Duan, Yunhui You, Weiru Zhang, Hongjun Zhao, Yanli Xie, Yaou Zhou, Wangbin Ning, Tong Li, Sijia Liu, Honglin Zhu, Xiaoyun Xie, Ying Jiang, Shiyao Wu, Weijia He, Yisha Li

Published in: Rheumatology International | Issue 4/2017

Login to get access

Abstract

The aim of the study was to measure the diagnostic values of biomarkers of bacterial infection in idiopathic inflammatory myopathy (IIM) patients. The serum and clinical data of 82 IIM patients with/without bacterial infection were collected. Concentrations of soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells 1 (sTREM-1), procalcitonin (PCT) and C-reactive protein (CRP) were measured in IIM patients and healthy controls. There were no significant differences in serum suPAR and sTREM-1 levels between healthy controls and non-infection IIM patients. Serum levels of suPAR, sTREM-1, PCT and CRP measured in this study were significantly higher in the IIM patient group with concurrent infection than in the non-infection IIM patient group (p < 0.05). The biomarker suPAR showed the highest diagnostic value with sensitivity, specificity, positive predictive value and negative predictive value of 81.6, 77.3, 75.6 and 82.9%, respectively. Combining suPAR negative and CRP negative to rule out bacterial infection in IIM patients provides a very high specificity of 97.4%. Both suPAR and CRP positive to confirm bacterial infection give the specificity of 90.9%. The inflammatory biomarkers suPAR, sTREM-1, PCT and CRP offer diagnostic accuracy in detecting bacterial infection in IIM patients. Particularly, suPAR is the most sensitive and specific biomarker to predict bacterial infection in IIM patients. Combination of suPAR and CRP serum levels provides an even better confirmation of bacterial infection.
Literature
8.
go back to reference Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY et al (2012) Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 64:3034–3042. doi:10.1002/art.34512 CrossRefPubMed Wu JY, Lee SH, Shen CJ, Hsieh YC, Yo PH, Cheng HY et al (2012) Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum 64:3034–3042. doi:10.​1002/​art.​34512 CrossRefPubMed
9.
go back to reference Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266:1926–1933PubMed Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266:1926–1933PubMed
16.
17.
go back to reference Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC et al (2004) Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 141:9–15CrossRefPubMed Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC et al (2004) Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 141:9–15CrossRefPubMed
19.
20.
go back to reference Murray SG, Schmajuk G, Trupin L, Lawson E, Cascino M, Barton J et al (2015) A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis. Arthritis Care Res (Hoboken) 67:673–680. doi:10.1002/acr.22501 CrossRef Murray SG, Schmajuk G, Trupin L, Lawson E, Cascino M, Barton J et al (2015) A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis. Arthritis Care Res (Hoboken) 67:673–680. doi:10.​1002/​acr.​22501 CrossRef
21.
go back to reference Yu J, Xu B, Huang Y, Zhao J, Wang S, Wang H et al (2014) Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 24:457–463. doi:10.3109/14397595.2013.844391 CrossRefPubMed Yu J, Xu B, Huang Y, Zhao J, Wang S, Wang H et al (2014) Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 24:457–463. doi:10.​3109/​14397595.​2013.​844391 CrossRefPubMed
22.
go back to reference Scire CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24:123–128PubMed Scire CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24:123–128PubMed
23.
go back to reference Sato H, Tanabe N, Murasawa A, Otaki Y, Sakai T, Sugaya T et al (2012) Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol 39:1517–1523. doi:10.3899/jrheum.111601 CrossRefPubMed Sato H, Tanabe N, Murasawa A, Otaki Y, Sakai T, Sugaya T et al (2012) Procalcitonin is a specific marker for detecting bacterial infection in patients with rheumatoid arthritis. J Rheumatol 39:1517–1523. doi:10.​3899/​jrheum.​111601 CrossRefPubMed
24.
go back to reference Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL (2009) Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis 68:1074–1075. doi:10.1136/ard.2008.098335 CrossRefPubMed Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL (2009) Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis 68:1074–1075. doi:10.​1136/​ard.​2008.​098335 CrossRefPubMed
25.
go back to reference Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL (1998) Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol 25:1531–1533PubMed Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL (1998) Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol 25:1531–1533PubMed
26.
go back to reference Kim HA, Jeon JY, An JM, Koh BR, Suh CH (2012) C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 39:728–734. doi:10.3899/jrheum.111044 CrossRefPubMed Kim HA, Jeon JY, An JM, Koh BR, Suh CH (2012) C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 39:728–734. doi:10.​3899/​jrheum.​111044 CrossRefPubMed
29.
30.
go back to reference Su L, Han B, Liu C, Liang L, Jiang Z, Deng J et al (2012) Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis 12:157. doi:10.1186/1471-2334-12-157 CrossRefPubMedPubMedCentral Su L, Han B, Liu C, Liang L, Jiang Z, Deng J et al (2012) Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis 12:157. doi:10.​1186/​1471-2334-12-157 CrossRefPubMedPubMedCentral
31.
go back to reference Savva A, Raftogiannis M, Baziaka F, Routsi C, Antonopoulou A, Koutoukas P et al (2011) Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 63:344–350. doi:10.1016/j.jinf.2011.07.016 CrossRefPubMed Savva A, Raftogiannis M, Baziaka F, Routsi C, Antonopoulou A, Koutoukas P et al (2011) Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 63:344–350. doi:10.​1016/​j.​jinf.​2011.​07.​016 CrossRefPubMed
32.
go back to reference Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J et al (2011) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 270:32–40. doi:10.1111/j.1365-2796.2011.02363.x CrossRefPubMed Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J et al (2011) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 270:32–40. doi:10.​1111/​j.​1365-2796.​2011.​02363.​x CrossRefPubMed
33.
go back to reference Kim J, Koh JK, Lee EY, Park JA, Kim HA, Lee EB et al (2009) Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin Exp Rheumatol 27:773–778PubMed Kim J, Koh JK, Lee EY, Park JA, Kim HA, Lee EB et al (2009) Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin Exp Rheumatol 27:773–778PubMed
34.
go back to reference Qin DD, Song D, Huang J, Yu F, Zhao MH (2015) Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China. Lupus 24:546–557. doi:10.1177/0961203314558857 CrossRefPubMed Qin DD, Song D, Huang J, Yu F, Zhao MH (2015) Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China. Lupus 24:546–557. doi:10.​1177/​0961203314558857​ CrossRefPubMed
35.
go back to reference Legany N, Toldi G, Distler JH, Beyer C, Szalay B, Kovacs L et al (2015) Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clin Chem Lab Med 53:1799–1805. doi:10.1515/cclm-2015-0079 CrossRefPubMed Legany N, Toldi G, Distler JH, Beyer C, Szalay B, Kovacs L et al (2015) Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clin Chem Lab Med 53:1799–1805. doi:10.​1515/​cclm-2015-0079 CrossRefPubMed
36.
go back to reference Manetti M, Rosa I, Milia AF, Guiducci S, Carmeliet P, Ibba-Manneschi L et al (2014) Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 73:1700–1709. doi:10.1136/annrheumdis-2013-203706 CrossRefPubMed Manetti M, Rosa I, Milia AF, Guiducci S, Carmeliet P, Ibba-Manneschi L et al (2014) Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 73:1700–1709. doi:10.​1136/​annrheumdis-2013-203706 CrossRefPubMed
39.
go back to reference Kaya S, Koksal I, Mentese A, Sonmez M, Sumer A, Yildirim SS et al (2013) The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. Int J Infect Dis 17:e1056–e1059. doi:10.1016/j.ijid.2013.04.004 CrossRefPubMed Kaya S, Koksal I, Mentese A, Sonmez M, Sumer A, Yildirim SS et al (2013) The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. Int J Infect Dis 17:e1056–e1059. doi:10.​1016/​j.​ijid.​2013.​04.​004 CrossRefPubMed
40.
go back to reference Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A et al (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15:R63. doi:10.1186/cc10037 CrossRefPubMedPubMedCentral Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A et al (2011) Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15:R63. doi:10.​1186/​cc10037 CrossRefPubMedPubMedCentral
Metadata
Title
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy
Authors
Yizhi Xiao
Hui Luo
Bin Zhou
Xiaodan Dai
Jing Huang
Liping Duan
Yunhui You
Weiru Zhang
Hongjun Zhao
Yanli Xie
Yaou Zhou
Wangbin Ning
Tong Li
Sijia Liu
Honglin Zhu
Xiaoyun Xie
Ying Jiang
Shiyao Wu
Weijia He
Yisha Li
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 4/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3609-x

Other articles of this Issue 4/2017

Rheumatology International 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.